Literature DB >> 3283542

The ras gene family and human carcinogenesis.

J L Bos1.   

Abstract

It has been well established that specific alterations in members of the ras gene family, H-ras, K-ras and N-ras, can convert them into active oncogenes. These alterations are either point mutations occurring in either codon 12, 13 or 61 or, alternatively, a 5- to 50-fold amplification of the wild-type gene. Activated ras oncogenes have been found in a significant proportion of all tumors but the incidence varies considerably with the tumor type: it is relatively frequent (20-40%) in colorectal cancer and acute myeloid leukemia, but absent or present only rarely in, for example, breast tumors and stomach cancer. No correlation has been found, yet, between the presence of absence of an activated ras gene and the clinical or biological features of the malignancy. The activation of ras oncogenes is only one step in the multistep process of tumor formation. The presence of mutated ras genes in benign polyps of the colon indicates that activation can be an early event, possibly even the initiating event. However, it can also occur later in the course of carcinogenesis to initiate for instance the transition of a benign polyp of the colon into a malignant carcinoma or to convert a primary melanoma into a metastatic tumor. Apparently, the activation of ras genes is not an obligatory event but when it occurs it can contribute to both early and advanced stages of human carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283542     DOI: 10.1016/0165-1110(88)90004-8

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  135 in total

Review 1.  Demystified ... oncogenes.

Authors:  Y L Wallis; F Macdonald
Journal:  Mol Pathol       Date:  1999-04

2.  Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.

Authors:  P Rieske; J Bartkowiak; A Szadowska; M Debiec-Rychter
Journal:  Mol Pathol       Date:  1999-04

3.  Is diabetes a risk factor for colorectal cancer?

Authors:  Hamed Khalili; Andrew T Chan
Journal:  Dig Dis Sci       Date:  2012-04-25       Impact factor: 3.199

4.  Ras levels and metalloproteinase activity in normal versus neoplastic rat mammary tissues.

Authors:  M Ballin; A R Mackay; J L Hartzler; A Nason; M D Pelina; U P Thorgeirsson
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

5.  A ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1.

Authors:  J E DeClue; J C Stone; R A Blanchard; A G Papageorge; P Martin; K Zhang; D R Lowy
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

6.  A genotypic mutation system measuring mutations in restriction recognition sequences.

Authors:  E Felley-Bosco; C Pourzand; J Zijlstra; P Amstad; P Cerutti
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

7.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

8.  Role of H-ras in the malignant progression of rat tracheal epithelial cells.

Authors:  G Cosma; F Hubbard; R J Jamasbi; A Marchok; S J Garte
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1.

Authors:  Shuhua Xia; Zhihong Chen; Lora W Forman; Douglas V Faller
Journal:  Cell Signal       Date:  2008-12-10       Impact factor: 4.315

10.  Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix.

Authors:  J J O'Leary; R J Landers; I Silva; V Uhlmann; M Crowley; I Healy; K Luttich
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.